Medtronic CE marks graft delivery system
This article was originally published in Clinica
Executive Summary
Medtronic (Minneapolis, Minnesota) has CE marked its Captivia delivery system for sale in Europe. The device delivers the Valiant thoracic stent graft, a minimally-invasive treatment for aneurysms and other lesions of the thoracic aorta. The Captivia system, used to perform endovascular aortic repair (EVAR), has also been launched onto the international market. However, both it and the Valiant graft are investigational in the US, where their use is limited to clinical trials.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.